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Abstract 
     Gold (I) coordinated N-heterocyclic carbenes containing appended redox cycling moieties 
were designed and analyzed for their ability to target the antioxidant network via multiple 
mechanisms in various human cancer cell models. Complexes containing either ferrocene or 
naphthoquinone redox cycling moieties were screened for inhibition of cell growth, inhibition of 
thioredoxin reductase (TrxR), and accentuation of exogenous ROS. The cell death pathway 
employed was determined by flow cytometry via detection of Annexin-V FITC. Furthermore, 
differential gene expression between treated cells and untreated cells revealed the induction of 
endoplasmic reticulum stress and unfolded protein response pathways.  
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Chapter 1. Introduction 
1.1 Network Pharmacology  
     Traditionally, new medications are designed to target a single gene or protein in the body. The 
idea is that by designing a small molecule to only interact with a single target, the potential side 
effects of the drug will be minimized. While these drugs can be effective for a time, they are 
usually limited to a single mechanism of action by their single target. Often, single target 
inhibition fails to alter phenotypic response due to signal redirection (Figure 1b). This adaptation 
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is problematic in anti-cancer therapy. When anticancer therapeutics have a single target, cancer 
cells can become resistant to the drug.1–3 In the clinic, the patient will then need higher doses to 
maintain the efficacy of the drug, or a new drug altogether. The second approach is problematic 
because there may not be another effective drug for the particular form of cancer in existence. 
However, a drug that targets multiple points along a pathway, instead of a single point, may 
work by multiple mechanisms (Figure 1c). This combination approach may overwhelm the target 
pathway and lead to greater alterations of the target phenotype, in addition to potentially 
reducing resistance, as the cells would have to develop resistance mechanisms for all of the 
mechanisms that the multimodal drug employs. We hypothesize that multimodal pathway 
targeting will result in phenotypic alterations that are controlled by said pathway. The 
antioxidant pathway was used as a model to test this hypothesis as it is a major intracellular 
defense pathway that is overexpressed in multiple cancers. 
Figure 1. Illustration regarding bimodal 
network targeting. a) Normal (green) 
signal transduction within a generic 
biological network. b) In the presence of a 
small molecule protein inhibitor, the 
current pathway is shut down; however 
no change in response is observed due to 
redirection of the signal transduction. c) 
It is hypothesized that biochemical 
targeting with the same protein inhibitor 
in conjunction with a small molecule 
capable of inducing general pathway 
stress (i.e. redox cycler) will shut down the network, resulting in a greater alteration of the 
phenotypic response. 
  
Small Molecule 
Protein Inhibitor
Minimal 
Change in 
Phenotypic 
Response
=
=
Pathway Stress 
Inducing Agonist
(i.e. Redox Cycler)
Alteration in 
Phenotypic 
Response
a)
X
b)
c)
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1.2 The Antioxidant Pathway 
     A mainstay in scientific education is an understanding of a biological system’s constant 
struggle to achieve homeostasis. The idea of homeostasis is that there are certain substances that 
are necessary for cells to live and function properly, and the cells need to have certain amounts 
of these substances. Vitamins, nutrients, enzymes, antioxidants, and scavengers are all examples 
of such Biologically Relevant Entities (BRE). If a cell does not have enough of a BRE, we call 
that a deficiency. An excess of a BRE leads to an 
overabundance. The functional range of a BRE lies 
between both extremes and provides the ideal 
concentration for proper biological function. In certain 
contexts, an inability to achieve cellular homeostasis 
may result in altered growth mechanisms or cell death. 
However, cancer progression and tumorigenesis have 
often been ascribed to cellular adaptations of such 
homeostatic alterations induced by external sources 
(Figure 2). This is the result of constant cellular 
alterations of BRE concentrations to maintain the 
functional range of that substance. 
Figure 2. Examples of stresses and responses in                                                                         
cells related to cancer progression and tumorigenesis. 
     Reactive Oxygen Species (ROS) are byproducts of normal cellular metabolism. They are 
generally small molecules with unpaired electrons (also known as free radicals) on oxygen atoms 
within the molecule. Free radicals are highly reactive, so the presence of ROS is very dangerous 
for the cell. Oxidation of lipids and fatty acids by ROS often result in cell membrane 
destruction.4–6 However, ROS are necessary for normal cell growth, as they play significant roles 
in iron homeostasis, anti-inflammatory pathways, and cell differentiation and proliferation.5,7 
This highlights the significance of the functional range for intracellular ROS. An overabundance 
of intracellular ROS is known as oxidative stress. This is important because oxidative stress is a 
common mode of toxicity in cells.4 
     The upper threshold on the functional range for ROS (between the functional range and 
oxidative stress) is maintained by antioxidant activity. Antioxidants are enzymes and small 
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molecules which act as reducing agents for reactive oxygen species. This neutralizes the threat 
posed to the cell by excessive ROS. Some known antioxidants include Vitamin C, Vitamin E, 
glutathione, superoxide dismutases (SODs), and thioredoxin.4,6 Thioredoxin is found in almost 
all living things. It is known to reduce ROS directly as well as regenerate several other 
antioxidants found in the cell. Thioredoxin itself is regenerated by the enzyme thioredoxin 
reductase (TrxR), which together form the thioredoxin system of antioxidant activity. 
Thioredoxin reductase is also known to reduce multiple targets and regenerate multiple 
antioxidants. While most antioxidants, including thioredoxin, utilize thiol-sulfhydryl chemistry 
for redox maintenance of ROS, thioredoxin reductase utilizes both cysteine and selenocysteine 
residues in its active site.6,8,9 
     There are 3 distinct human thioredoxin systems. Trx-1 and TrxR1 are found in the cytoplasm 
of most human cells. Trx-2 and TrxR2 are found in the mitochondria of human cells. SpTrx and 
TrxR3 (now renamed TGR) are found in human spermatozoa.6 Interestingly, TGR reduces both 
Trx and glutathione, hence the new name. Inhibition of Trx1 is generally therapeutic for those 
with arthritis. Inhibition of the mitochondrial thioredoxin system is lethal to cells.8,9 The 
thioredoxin system is known to be overexpressed in cancer cells.10–12 
1.3 Targeting of the Antioxidant Pathway 
     It has long been known that platinum-containing compounds, arsenic-containing compounds, 
gold (I) compounds, and quinone-containing compounds13,14 inhibit the activity of thioredoxin 
reductase.6 Several gold (I) phosphines have been shown to have therapeutic value due to their 
binding with intracellular protein targets, including TrxR.8,9 This is done by ionic interactions 
with the selenocysteine residues in the active site of the enzyme. By introducing gold (I) N-
heterocyclic carbenes to cells, TrxR activity can be significantly diminished. This lowers the 
threshold between oxidative stress and the functional range of reactive oxygen species in the cell. 
Prolonged exposure to gold (I) N-heterocyclic carbenes is toxic to cancer cells.  
     Another mechanism used in modulation of ROS-regulated pathways is introducing ROS-
generating substances to the cells. Ferrocene has been studied for decades for this purpose. The 
iron core of a ferrocene has an oxidation state of 2+. It can undergo the Fenton reaction with 
hydrogen peroxide (a common intracellular reactive oxygen species) to produce hydroxyl 
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radical(s) and ferrocenium. In the presence of reducing species, such as NADH or NADPH, the 
iron 3+ of the ferrocenium can then be reduced to iron 2+ to regenerate the ferrocene. Another 
redox-active functionality that can be used to generate intracellular ROS is quinone. Quinones 
can undergo one-electron redox reactions, forming a semi-quinone in the process, or two-
electron redox reactions, forming hydroquinone. This is especially interesting from a 
pharmacological standpoint because quinones are biologically active and are already found 
throughout the cell. Common intracellular quinone-containing compounds include all forms of 
Vitamin K, Coenzyme Q (ubiquinone), and plastoquinone. We hypothesize that a single 
molecule capable of 1) reducing intracellular antioxidants via protein inhibition and 2) 
accentuating oxidative stress via redox cycling will disrupt ROS homeostasis via multiple 
mechanisms and result in alterations of growth stress phenotypes. 
1.4 Cell Models Utilized 
     There are many cell lines that can be used for evaluation of the toxicological effects of 
compounds. The cell lines employed by the Arambula group are A549, A2780, A2780CP, and 
PC-3. The Arambula group works primarily with A549 because it is well-suited for studying 
intracellular ROS homeostasis.   
     The A549 cell line was established by D.J. Giard et al. in 1972, using epithelial cells from a 
lung carcinoma. The patient the cells came from was a 58-year-old Caucasian man. The cells 
have a doubling time of about 22 hours and can be transfected. A549 cells are not identical, and 
usually have 64-67 chromosomes.15 They can have multiple copies of the X and/or Y 
chromosome or even absence of the Y chromosome.16 This is significant because a healthy, 
normal human cell should have 46 chromosomes, of which there will be two X chromosomes, or 
one X and one Y. Because these cells came from a man, it is expected that they would have one 
X chromosome and one Y chromosome each. The A549 cell line is known to be tumorigenic, 
which means that these cells can form a tumor if injected into an organism.17 Because these cells 
are from lung tissue, they have an elevated tolerance for intracellular ROS. A549 is known to 
overexpress the antioxidant thioredoxin reductase relative to normal cells.10,12 For this reason, 
A549 is a good model to use when studying intracellular ROS levels and TrxR activity. This cell 
line is wild-type for the p53 tumor suppressor gene.18 
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     The A2780 cell line was established by T. H. Ward in 1984 from an ovarian epithelial 
adenocarcinoma. It has a doubling time of 24 hours. It is also very easy to kill these cells because 
the patient from which it was derived had never undergone any anticancer treatment at the time. 
Two treatment-resistant lines were derived from this line (A2780CP and A2780ADR) by treating 
the cells with common chemotherapeutics for several consecutive passages. A2780CP is resistant 
to cisplatin, and has a doubling time of 48 hours. These cells require patience. A2780 and 
A2780CP are not available through the ATCC.19–23 Our cells are from the M. D. Anderson 
Cancer Center, courtesy of Dr. Zahid Siddik and Dr. Guangan He. Also, they are both wild-type 
for the p53 gene.18 
     The PC-3 cell line was established by M.E. Kaighn et al. in 1979. The cells that were used 
were from prostate cancer that had metastasized to the nearby bone. PC-3 cells are epithelial 
cells from that bone, and the tumor was a grade 4 adenocarcinoma.  The patient was a 62-year-
old Caucasian male. PC-3 can be transfected, and has a doubling time of about 25 hours. It is 
tumorigenic, which means that when these cells are injected into mice, they form tumors (PC-3 
happens to form tumors 100% of the time, reportedly). This is important to note, because some 
researchers have erroneously thought that only males need to be concerned about incidents 
involving PC-3. The fact that it metastasized to bone suggests that the cell line is in fact 
hazardous to anyone who has bones. These cells have about 62 chromosomes, and none of them 
have an identifiable Y chromosome.24 PC-3 does not have a functional p53 gene.18 
1.5 Previous Work 
     In an effort to determine whether both paradigms for modulating intracellular ROS levels 
could be utilized by a single molecule, several compounds were co-designed by Dr. Arambula 
and Dr. Kuppuswamy Arumugam. The first three compounds under the numbering system used 
were imidazolium salts, which were synthesized in the Arumugam lab according to literature 
procedures,25–31 and used as precursors in the synthesis of all other compounds in the library. 
Compound 1 is an N-heterocyclic carbene. Compound 2 is an N-heterocyclic carbene with one 
ferrocene per molecule. Compound 3 has two ferrocenes per molecule appended to the N-
heterocyclic carbene core. Compounds 4-7 are generally referred to as the first generation of 
compounds in this project. Compound 4 has the gold (I) N-heterocyclic carbene moiety, but 
lacks ferrocene moieties. Compound 5 has the gold (I) N-heterocyclic carbene moiety, and two 
15 
 
ferrocene moieties per molecule. Compound 6 features a gold (I) N-heterocyclic moiety and four 
ferrocene moieties per molecule. Compound 7 is the ferrocenium of compound 5, meaning that 
the iron in both ferrocenes per molecule is at a different oxidation state (3+) than that of 
compound 5 (2+). These compounds were featured in Arambula et al. 2016.  
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Figure 3. Structures of compounds 1-7. 
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     Auranofin (Aura) is an FDA-approved anti-rheumatic drug that has been shown to inhibit 
thioredoxin reductase. It is a glucose analog with a gold (I) phosphine moiety.8,9 Auranofin was 
used as a control for TrxR inhibition in the lipoate reduction assay, and its anti-proliferative 
potency was tested by the MTT assay for comparison purposes.        
A
u
 
Figure 4. Structure of Auranofin. 
Cell Proliferation as Determined by MTT Assay 
     The IC50 value of Auranofin in A549 was measured. This was done largely for comparison 
purposes, as slight protocol variations from one lab to the next make potency comparisons using 
data generated by another lab difficult. In the case of Auranofin, our average IC50 value was 1.14 
+/- 0.15 µM. This allows us to make more accurate comparisons between our compounds and 
previously-established cytotoxic compounds, such as Auranofin. 
     The IC50 value of compound 6 in A549 was verified at Georgia Southern. Statistically, there 
was no discernable difference between values obtained at Georgia Southern by the author and 
values obtained in Texas by Dr. Arambula. Compound 6 has an average IC50 of 0.149 +/- 0.024 
µM. Compound 6 is the most potent of these compounds, followed by compound 5 (0.39 +/- 
0.01 µM), then compound 4 (0.71 +/- 0.03 µM). This trend shows increased toxicity of the 
experimental compounds as the number of ferrocene subunits per molecule is increased. 
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Table 1. Average IC50 values of compounds in A549 after three days incubation. Literature 
values provided for Cisplatin and Carboplatin for comparison. 
Compound(s) Average IC50 Value (µM) Standard Error 
2 6.4 1.1 
3 13 1.5 
4 0.71 0.03 
5 0.39 0.01 
6 0.14 0.03 
1:2 4:3 0.61 0.05 
Auranofin + 3 1.61 0.09 
Auranofin 1.67 0.05 
Cisplatin 0.98a --- 
Carboplatin 27a --- 
 
     During previous work in Texas, compounds 5 and 7 were determined to yield 
indistinguishable results for the MTT assay. This was re-examined at Georgia Southern, to the 
same effect. There was no discernable difference between the A549 cells exposed to compound 5 
and A549 cells exposed to the same concentrations of compound 7 (p=0.5066).  
 
 
  
                                                 
a
 Values from a currently unpublished work by Prof. Jonathan L. Sessler and Prof. Zahid Siddik. 
Cells were incubated with compound for 120 hr. 
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Figure 5. Average MTT data and standard error for compounds 5 and 7 in A549. 
Determination of Intracellular ROS 
     In previous work by the Arambula group, it was shown that Auranofin and compound 4 
generated about equal amounts of intracellular ROS after 6 hours incubation at 2.5 µM 
compound. It was also shown that the amount of intracellular ROS in A549 significantly 
increases with the addition of ferrocene subunits to the gold (I) N-heterocyclic core of the 
compounds. Compound 5 generates more intracellular ROS than compound 4, but less than 
compound 6. The intracellular ROS increase in A549 cells exposed to 2.5 µM of compounds 5 or 
6 is significantly greater than that of cells exposed to 2.5 µM Auranofin at 6 hours of 
incubation.31 This shows that compounds 4-6 are capable of increasing intracellular ROS levels. 
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Figure 6. Relative intracellular ROS increase of A549 cells after 6 hours incubation with 
2.5 µM compound. A is for Auranofin. Figure courtesy of Dr. Arambula. 
Inhibition of Intracellular Thioredoxin Reductase by Lipoate Reduction Assay
 
Figure 7. Normalized lipoate reduction and standard error in A549 at 2.5 µM compound, 
180 minutes after addition of lipoate. Figure courtesy of Dr. Arambula. 
     As discussed in Arambula et al. 2016, Auranofin inhibits about 30% of intracellular TrxR 
activity. A549 cells incubated with compounds 2 and 3 did experience some inhibition of 
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thioredoxin reductase, but not a great deal. Cells exposed to compounds 4, 5, and 6 display about 
50% inhibition of intracellular thioredoxin reductase. This shows that compounds 2-6 do inhibit 
the antioxidant enzyme thioredoxin reductase.31 
Conclusions from Previous Work 
     The work published in Arambula et al. 2016 showed that compounds 4, 5, and 6 were all 
highly toxic to A549 lung cancer cells. They all induced elevated levels of intracellular ROS and 
inhibited the activity of intracellular TrxR. These compounds successfully targeted multiple 
points along the antioxidant pathway, leading to their high potency.31  
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Chapter 2. Small Molecule Design Parameters and Approach 
2.1 Introduction of Compounds 8-11 
     To test our hypothesis of multi-modal pathway targeting, a small library of complexes were 
designed and synthesized in collaboration with Professor Kuppuswamy Arumugam at Wright 
State University. For these studies, quinone-based moieties (via naphthoquinone) were chosen 
due to their biological relevance. Lead compound 9 consists of two naphthoquinone moieties 
appended to an N-heterocyclic carbene (NHC). It is proposed that the dual combination of 1) a 
redox cycling agent to increase exogenous ROS and 2) a Au(I)-NHC to inhibit a reducing 
metabolite (i.e. TrxR) to lower the upper threshold of the functional range will disrupt 
antioxidant homeostasis from both ends, thus overwhelming the network and promoting cell 
death (Figure 8). Naphthoquinone precursor 8 in addition to mono-NHCs 10 and 11 provide both 
charged (non-metal coordinated) and neutral metal coordinated controls. These compounds will 
help develop a Structure Activity Relationship to elucidate parameters important in the design of 
metal coordinated NHC medicinal agents. 
 Figure 8. Mechanism-based rationale 
regarding a dual-targeting approach in 
drug design. A) Untreated cancer cells 
elicit a defined and tolerated endogenous 
ROS level. This level is below the threshold 
that induces cell death. B) Many small 
molecules are capable of accentuating 
exogenous ROS within the cancer, but may 
not reach the threshold, or require higher 
levels of redox cycler to overwhelm the 
system. C) Antioxidant inhibitors reduce 
the amount of reducing metabolite, thus lowering the upper threshold. D) The dual 
targeting approach proposes the use of a redox cycler to accentuate exogenous ROS in 
combination with a reducing metabolite inhibitor, which lowers the threshold. This 
combination will overwhelm the system and drive it towards death. 
      Doxorubicin (Dox) is an FDA-approved anticancer therapeutic, which is currently in use. It 
is structurally similar to the second generation of our compounds in that it has a naphthoquinone 
moiety.32 Doxorubicin was also studied by MTT assay, lipoate reduction assay, thermal 
denaturation, and flow cytometry for intracellular ROS and apoptosis detection.     
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Figure 9. Structures of compounds 8-11 and Doxorubicin. 
2.2 Utility of Quinone-based Moieties in Targeting the Antioxidant Pathway 
     While the first generation of compounds utilized ferrocene moieties for redox cycling, the 
second generation compounds utilized quinones for redox cycling. Quinones are known to be 
redox-active in the cell, as they are involved in the electron transport chain in mitochondria, and 
in photosynthesis. Quinones can cycle two electrons per moiety (from quinone to semiquinone to 
hydroquinone and back),4 while ferrocenes can only cycle one electron per moiety (from 
ferrocene to ferrocenium and back). Quinone incorporation within our design is proposed to 
increase intracellular exogenous ROS. 
2.3 Utility of Au(I) NHCs in Targeting the Antioxidant Pathway 
     The gold (I) bis-N-heterocyclic carbene moiety has been shown to be effective in inhibition of 
intracellular TrxR.8,9 Inhibition of the antioxidant enzyme thioredoxin reductase should 
indirectly lead to an increase in intracellular ROS, which should lead to cell death. Compound 4 
from the first generation of compounds is intended to show the effect of just the gold (I) bis-N-
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heterocyclic carbene moiety. Compound 9 incorporates both the naphthoquinone and gold (I) 
bis-N-heterocyclic carbene. 
2.4 Mono vs. Bis/ Gold vs. Silver 
     Comparison of compounds 9 and 11 is intended to be beneficial in revealing the role of the 
second N-heterocyclic carbene moiety in the experimental small molecules. Compound 11 is a 
naphthoquinone with a gold (I) mono-N-heterocyclic carbene moiety. Compound 10 is intended 
to show the difference in efficacy between gold and silver as the transition metal complexed with 
the N-heterocyclic carbene when compared with compound 11. 
2.5 Assays and Tests Introduced for Study of 8-11 
     A few new assays and tests were introduced for work involving the new compounds. These 
include the FITC Annexin V Apoptosis Assay, determination of DNA binding by thermal 
denaturation, the zebrafish toxicity screening, and the in vivo studies of compounds 6 and 9 in 
xenografts. 
     An FITC Annexin V Apoptosis Detection Kit was used to determine whether treated cells 
were undergoing apoptosis or necrosis. Annexin V is a protein that binds the phospholipid 
phosphatidylserine. During apoptosis, phosphatidylserine that was on the inner membrane of the 
cell shifts to the outer membrane of the cell. This allows interaction of extracellular Annexin V 
with shifted phosphatidylserine. The FITC-Annexin V kit that we used utilizes this by affixing a 
fluorophore to the Annexin V, such that when Annexin V binds exposed phosphatidylserine, the 
FITC fluoresces. By simultaneously treating cell populations with propidium iodide (which only 
penetrates dead cells through the gaps in their membranes) and FITC-Annexin V, cells with high 
red fluorescence due to propidium iodide penetration can be excluded from the population of 
interest. Under these conditions, live, thriving cells will not fluoresce red (with propidium 
iodide) or green (with FITC-Annexin V). Also under these conditions, cells in early apoptosis 
will fluoresce green, but not red. Any cells under these conditions that fluoresce red are either 
dead or very nearly there, and the pathway by which they got there cannot be determined unless 
they were previously monitored in a time-dependent fashion (do the cells go from no 
fluorescence, to green fluorescence, then both green and red, or do they go directly from no 
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fluorescence to red fluorescence?). Cells that go directly from no fluorescence to red 
fluorescence after constant monitoring are understood to undergo necrosis.33    
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Chapter 3. Results 
3.1 Cell Proliferation by MTT Assay 
     In May of 2015, compounds 8 and 9 were first introduced to the cells. Compound 8 is the 2nd 
generation’s equivalent of compound 3 from the 1st generation of compounds.31 As such, it 
displayed a lower potency in inhibiting cell proliferation than compound 9. The IC50 value of 8 
was 1.31 +/- 0.22 µM in A549. This was significantly different from compound 9’s IC50 of 0.076 
+/- 0.013 µM in A549 (p < 0.0001). The high potency of compound 9 further supported the 
hypotheses behind the design of the compound, and resulted in compound 9 joining compound 6 
on the short list of lead compounds for potential drug development.  
     As discussed in Arambula et al. 2016, it is important to know if the increased activity of lead 
compound 9 is due only to the presence of all moieties in a given proportion, or if there is some 
advantage to having all of the moieties on a single molecule. This is why cocktails of Auranofin 
+ 3 and 3+4 were studied during development of lead compound 6.31 The cocktail used for this 
purpose for compound 9 was a 1:2 molar ratio of 4:8. Compound 4 was the gold (I) N-
heterocyclic carbene in this mixture, and compound 8 was the naphthoquinone. The average IC50 
value of 1:2 4:8 in A549 was 0.197 +/- 0.057 µM, which was a statistically different value from 
that of compound 9 in A549 (0.076 +/- 0.013 µM, p=0.0484). The cocktail was more potent than 
compound 4 alone in A549 (0.59 +/- 0.12 µM, p=0.009) and compound 8 alone in A549 (1.31 
+/- 0.22 µM, p=0.0011). The potency of the cocktail was indistinguishable from that of 
Doxorubicin (0.103 +/- 0.024 µM, p=0.566) or compound 6 (0.149 +/- 0.024 µM, p=0.7059).         
                            
Figure 10. Structures of 1:2 4:8 cocktail and compound 9. 
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     In A2780, the average IC50 value for compound 8 was 0.159 +/- 0.052 µM, which is not 
significantly different from that of compound 9 at 0.041 +/- 0.013 µM (p=0.0748). This is 
probably because the A2780 is difficult to work with, as it is very sensitive and cells of this line 
die easily. This caused some erratic responses from the cell line. Given time, more work could be 
done with these compounds in this cell line, and the error could be cleaned up a bit, which may 
make a difference in compound potency more evident. In A2780CP, the average IC50 value of 
compound 9 was 0.054 +/- 0.006 µM. This was significantly different from that of compound 8, 
which was 0.703 +/- 0.119 µM (p=0.0064). In PC-3, there was no discernable difference between 
the potency of compound 8 (0.136 +/- 0.020 µM) and compound 9 (0.104 +/- 0.015 µM, 
p=0.2513).  
          Compound 10 was first introduced to the A549 cell line in April of 2016. The IC50 value of 
compound 10 in A549 was determined to be 0.61+/- 0.04 µM. This potency is distinct from all 
other compounds studied except compound 4 (p=0.8545). Compound 11 has an average IC50 
value of 12.06 +/- 0.18 µM in A549. This value is statistically different from that of all other 
compounds tested (p<0.0001). The compounds displayed varying levels of toxicity, with 
compounds 6 and 9 being the most potent, due to their redox capabilities and gold(I) NHC 
centers. 
Table 2. IC50 values of compounds in A549. 
Compound(s) Average IC50 (µM) Standard Error 
4 0.59 0.12 
6 0.149 0.024 
8 1.31 0.22 
9 0.076 0.013 
10 0.61 0.04 
11 12.06 0.18 
Auranofin 1.14 0.15 
Doxorubicin 0.103 0.024 
1:2 4:8 0.197 0.057 
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Table 3. P-values of t-tests comparing IC50 values of compounds in A549. Values less than 
0.05 are significant. 
 Dox 8 9 Aura 1:2 4:8 4 6 10 
Dox --- <0.0001 0.0753 <0.0001 0.566 0.0005 0.8114 <0.0001 
8 <0.0001 --- <0.0001 0.9686 0.0011 0.0693 0.0008 0.0474 
9 0.0753 <0.0001 --- <0.0001 0.0484 <0.0001 0.0117 <0.0001 
Aura <0.0001 0.9686 <0.0001 --- 0.0006 0.0479 0.0005 0.0281 
1:2 4:8 0.566 0.0011 0.0484 0.0006 --- 0.009 0.7059 0.0001 
4 0.0005 0.0693 <0.0001 0.0479 0.009 --- 0.0041 0.8545 
6 0.8114 0.0008 0.0117 0.0005 0.7059 0.0041 --- <0.0001 
10 <0.0001 0.0474 <0.0001 0.0281 0.0001 0.8545 <0.0001 --- 
11 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
 
Table 4. Average IC50 values and standard error of compounds in A2780, A2780CP, and 
PC-3. 
Cell Line Compound Average IC50 
(µM) 
Standard 
Error 
A2780 6 0.194 0.002 
8 0.159 0.052 
9 0.041 0.013 
A2780CP 6 0.120 0.003 
8 0.703 0.119 
9 0.054 0.006 
PC-3 6 0.475 0.079 
8 0.136 0.020 
9 0.104 0.015 
 
Table 5. P-values of t-tests comparing IC50 values of compounds in A2780, A2780CP, and 
PC-3. Values less than 0.05 are significant. 
 Cell Line A2780 A2780CP PC-3 
Cell Line Compound 6 8 9 6 8 9 6 8 9 
A2780 
6 --- 0.8799 <0.0001 <0.0001 0.0068 <0.0001 0.0119 0.0457 0.0014 
8 0.8799 --- 0.0748 0.4326 0.0209 0.1543 0.0481 0.4178 0.2142 
9 <0.0001 0.0748 --- 0.0055 0.0018 0.4732 0.0016 0.0079 0.0214 
A2780CP 
6 <0.0001 0.4326 0.0055 --- 0.0103 0.0008 0.0126 0.5983 0.4768 
8 0.0068 0.0209 0.0018 0.0103 --- 0.0064 0.1757 0.0006 0.0010 
9 <0.0001 0.1543 0.4732 0.0008 0.0064 --- 0.0064 0.0267 0.0568 
PC-3 
6 0.0119 0.0481 0.0016 0.0126 0.1757 0.0064 --- 0.0010 0.0013 
8 0.0457 0.4178 0.0079 0.5983 0.0006 0.0267 0.0010 --- 0.2513 
9 0.0014 0.2142 0.0214 0.4768 0.0010 0.0568 0.0013 0.2513 --- 
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Figure 11. Average MTT data and standard error for Auranofin, 1:2 4:8 cocktail, 4, and 9 
in A549. 
 
Figure 12. Average MTT data and standard error for compounds 8, 9, Doxorubicin, and 
Auranofin. 
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Figure 13. Average MTT data and standard error for compounds 6, 8, 9, 10, and 11. 
 
Figure 14. Average MTT data and standard error for compounds 10, 11, Doxorubicin, and 
Auranofin. 
3.2 Cellular Uptake as Determined by Lowry Assay and ICP-MS 
     After some fine-tuning of the protocol (how much of which acids to use for digestion, how 
and when to quantify the cells in each sample, etc.), we arrived at the protocol described in 
Materials and Methods. This protocol allows for normalization of the data obtained from the 
Inductively-Coupled Plasma Mass Spectrometer (ICP-MS) by the Modified Lowry Assay. 
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Samples were generally found to contain about 20,000 µg/mL protein. According to the 
normalized ICP-MS data, as shown in Figure 15, about 4 times more gold is getting into the cells 
treated with Auranofin than cells treated with either of compounds 4 or 9. While this is slightly 
disappointing from an uptake perspective, it may indicate that compounds 4 and 9 are more 
potent per molecule than Auranofin. The IC50 value of Auranofin is about twice that of 
compound 4, and 15 times that of compound 9. Keeping in mind that a lower IC50 value denotes 
higher anti-proliferative potency, this could mean that our compounds are far more potent per 
molecule than Auranofin.  
 
Figure 15. Average intracellular gold (normalized to protein) after exposure of A549 to 
varying concentrations of Auranofin, 4, and 9, with standard error. Figure courtesy of Dr. 
Arambula. 
3.3 Serum Protein Binding Study 
     An important piece of information to know in the development of potential therapeutics is the 
amount of free drug in blood serum after drug administration. In an effort to determine the 
amount of free drug in blood serum after administration, the concentration of gold not bound to 
serum proteins over the course of time was monitored by ICP-MS. Fetal bovine serum that has 
not been heat-inactivated is commonly used for this purpose.34 There is a possibility that the drug 
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subunits disassociate in serum such that measuring free gold is not equivalent to measuring free 
drug. For this reason, the distinction between free gold and free drug must be made at this time. 
Future experimentation utilizing LC-MS for detection of organic subunits is of great interest to 
the group, but has not yet been scheduled. As shown in Figure 16, the gold in Auranofin binds 
serum proteins within 6 hours, while the gold in compounds 4 and 9 remains free even after 72 
hours. 
 
Figure 16. Average percent free gold at varying time points after introduction of 
Auranofin, 4, and 9 to fetal bovine serum at 37°C, with standard error. Graph courtesy of 
Dr. Arambula. 
3.4 Determination of Intracellular ROS 
      In 2016, the Arambula group had the opportunity to use the flow cytometer at UT Austin, so 
intracellular ROS data for compounds 8 and 9, the 1:2 4:8 cocktail, and Doxorubicin. Figure 17 
shows the dose-responsive nature of the intracellular ROS increase after 6 hours incubation with 
compound 9.  
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Figure 17. Overlaid flow cytometry data for ROS levels in A549 cells incubated with 
varying concentrations of compound 9 for 24 hours. The population depicted in black is the 
vehicle control, the green population is 1.25 µM 9, the population in blue is 2.5 µM 9, and 
the population in red is 5 µM 9. Figure courtesy of Dr. Arambula. 
 
Figure 18. Relative intracellular ROS levels of A549 after 6 hours incubation with varying 
concentrations of compound. Figure courtesy of Dr. Arambula. 
     As can be seen in Figure 18, compound 9 and the 1:2 4:8 cocktail increased intracellular ROS 
levels the most, with at least a 20-fold increase at 2.5 µM compound. The difference between 
this increase and the increase caused by compound 8 alone and compound 4 alone lead us to 
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believe that the effect of having both the quinone and the N-heterocyclic carbene present on the 
molecule is at least additive, if not synergistic. At 2.5 µM, both compounds 4 and 8 displayed 
about a 10-fold increase in intracellular ROS. Surprisingly, mono-NHC 11 provided no 
detectable accentuation of intracellular ROS under the assay conditions. While its mechanism 
has yet to be fully elucidated, it is possible that the more reactive Au-Cl bond within 11 may be a 
site of protein sequestration. Alternatively, the neutrality within 11 (relative to the single positive 
charge within 9, 4, 8) may prevent or create an alternative route of cellular uptake, thus leading 
to its reduced activity.35 Despite this, lead compound 9 and charged controls (i.e. 4, 8) were able 
to generate intracellular ROS, fulfilling one half of the proposed mechanism of action. It can be 
noted that while Auranofin is known to inhibit TrxR,8,9 there is not much of an intracellular ROS 
increase in cells treated with Auranofin relative to cells treated with our experimental 
compounds. This leads us to believe that the redox cycling of the naphthoquinones is largely 
responsible for the increase. 
3.5 Inhibition of Intracellular Thioredoxin Reductase by Lipoate Reduction Assay 
 
Figure 19. Normalized lipoate reduction with standard error in A549 over 3 hours, after 6 
hours incubation in 0.625 µM compound. 
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Figure 20. Normalized lipoate reduction with standard error in A549 over 3 hours, after 6 
hours incubation in 5 µM compound.                       
 
Figure 21. Normalized lipoate reduction and standard error in A549 at 5 µM and 0.625 µM 
compound, 180 minutes after addition of lipoate. 
     Because Auranofin is known to inhibit TrxR activity, it was used as a positive control for 
TrxR inhibition. Auranofin inhibited TrxR activity significantly at all concentrations studied 
(p≤0.0001). This can be seen in Figures 20-25, 34-39, 46, and 47, and Table 12. Auranofin 
inhibited thioredoxin reductase activity from 29 +/- 6 % inhibition at 0.156 µM to 91 +/- 2 % 
inhibition at 5 µM. Doxorubicin was used for the purpose of comparing the activity of our 
naphthoquinone compounds against a structurally-similar FDA approved anticancer drug. 
Although Doxorubicin has been shown to inhibit TrxR in human rhabdomyosarcoma cells, we 
found that it does not inhibit TrxR in A549 within 9 hours of being introduced to the cells.13 
Statistically, there was no difference between the untreated cells and cells treated with 5 µM 
Doxorubicin, or any lower concentrations (p=0.0898 - 0.5855).  
     Of the other compounds run, compound 9 and the 1:2 4:8 cocktail showed significant TrxR 
inhibition at all concentrations studied (p≤0.0012 and p≤0.0182, respectively). Compound 9 
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activity ranged from about 33 +/- 2 % inhibition of TrxR at 0.156 µM to 79 +/- 2 % inhibition at 
5 µM. The 1:2 4:8 cocktail displayed 18 +/- 3 % inhibition of thioredoxin reductase at 0.156 µM 
to 72 +/- 4 % inhibition at 5 µM. With the exception of the response seen at 0.3125 µM 4 
(p=0.1276), compound 4 alone significantly inhibited TrxR at all studied concentrations 
(p≤0.0481). Compound 4 alone inhibited TrxR from 11 +/- 3 % inhibition at 0.156 µM to 60 +/- 
1 % inhibition at 5 µM. No significant inhibition was seen at 0.3125 µM 4. Compound 8 was 
indistinguishable from the control at concentrations of 1.25 µM and below (p≥0.1170). However, 
at 2.5 µM and 5 µM, compound 8 showed extremely significant inhibition of thioredoxin 
reductase (p<0.0001). At 2.5 µM, compound 8 inhibited 33 +/- 4 % TrxR activity, and at 5 µM, 
it inhibited 57 +/- 5 % TrxR activity. Compound 10 showed significant inhibition of TrxR at 
1.25 µM and above (p<0.0001). At these concentrations, compound 10 is indistinguishable from 
Auranofin with regard to enzyme inhibition. Compound 11 did not significantly inhibit TrxR at 
any concentration below 5 µM. All of the compounds studied, including Auranofin and 
Doxorubicin, had a generally linear, dose-responsive effect on TrxR activity (although the slope 
of that line is about 0 for Doxorubicin). This is shown in Figures 40-45. Compounds 8-10 and 
the 1:2 4:8 cocktail showed significant inhibition of thioredoxin reductase at 5 µM, 
demonstrating a second mechanism of action (with intracellular ROS increase being the first).  
  
Figure 22 . Normalized lipoate reduction with standard error in A549 over 3 hours, after 6 
hours incubation in 0.625 µM compound.                    
0
0.2
0.4
0.6
0.8
1
1.2
0 50 100 150 200
N
o
rm
a
li
ze
d
 L
ip
o
a
te
 
R
e
d
u
ct
io
n
Time after Lipoate Introduction (minutes)
control
9
10
11
Aura
37 
 
 
Figure 23. Normalized lipoate reduction with standard error in A549 over 3 hours, after 6 
hours incubation in 5 µM compound.                           
Figure 24. Normalized lipoate reduction with standard error in A549 at 0.625 µM and 5 
µM compound, 180 minutes after addition of lipoate. 
3.6 Determination of Cell Death Pathway by FITC Annexin V 
     Differentiation in cell death mechanisms is imperative to a full understanding in drug 
mechanistic action. Chaotic cell death such as  necrosis is often viewed as problematic due to its 
lack of control and premature release of active biomolecules.36 Apoptosis, on the other hand, is 
controllable and normal. Some anomalies, such as webbed feet and toes, are actually due to 
failure of the involved cells to undergo apoptosis.37 It has been well established that Doxorubicin 
and Au(I) based complexes such as Auranofin induce controlled cell death via apoptosis in a 
variety of human cell lines.32,38–40 In addition, quinone complexes, despite their inhibitory 
mechanism, also have been shown to induce apoptosis.40 To further elucidate the mechanism of 
action regarding 9 in the A549 lung cancer model, flow cytometry was utilized to deduce the 
induction of apoptosis via fluorescent staining with Annexin-V. In brief, plated exponential 
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growth phase A549 cells were exposed to various concentrations of 9 and incubated for 24 hr. At 
that point, all cells (adhered and floating) were collected, washed, and stained with fluorescein 
labeled Annexin-V and propidium iodide (PI) and subjected to flow cytometry for the detection 
of both early stage apoptosis and late stage apoptosis/necrosis (cf. Figure 25). In a dose-
responsive manner, the detection of early-stage apoptosis, as assessed by Annexin-V binding 
phosphatidylserine on the still intact and impermeable cell membrane (resulting in only FITC 
fluorescence), became evident. The treatment of A549 cells with Doxorubicin (a known inducer 
of apoptosis) provided similar results in both early and late stage apoptotic quadrants thus 
suggesting that complex 9 induces controlled cell death via an apoptotic mediated mechanism. 
                
Figure 25. Representative Annexin V flow cytometry data for varying concentrations of 
compound 9 at 24 hours of incubation. Figure courtesy of Dr. Arambula. 
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Figure 26. Representative Annexin V flow cytometry data for varying concentrations of 
Doxorubicin at 24 hours of incubation. Figure courtesy of Dr. Arambula. 
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Figure 27. Representative Annexin V flow cytometry data for 1.25µM Doxorubicin after 
24, 48, and 72 hours incubation. Figure courtesy of Dr. Arambula. 
3.7 DNA Binding as Determined by Thermal Denaturation 
     Doxorubicin is known to act on cells by intercalating with DNA bases and stopping the 
function of topoisomerases by keeping the substrate away from the active site of the enzyme.32 
Due to the structural similarities between Doxorubicin and compounds 8 and 9, the ability of 
compounds 8 and 9 to bind DNA was evaluated by thermal denaturation studies. The concept 
behind thermal denaturation is that the temperature required to melt (or separate) a DNA duplex 
will change in the presence of a compound that affects the stability of the duplex. A compound 
that stabilizes the duplex will cause the melting temperature to rise above that of the duplex on 
its own. A compound that destabilizes the duplex will cause the melting temperature to fall 
below that of the duplex on its own. This change will be visible as a shift to the left or right of a 
curve showing the absorbance of the duplex at 260 nm at increasing temperatures. The data 
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collected shows that compounds 8 and 9 have a negligible effect on the melting temperature of 
the DNA duplex observed, which suggests that they do not bind to DNA. The data does clearly 
show that Doxorubicin stabilizes the duplex and raises the melting temperature, which is in line 
with previous literature.41 
 
Figure 28. Normalized absorbance of DNA and compound at 260 nm at varying 
temperatures, and average melting temperatures. NQImd is compound 8, and NQAuNHC 
is compound 9. Figure courtesy of Zarana Patel. 
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Chapter 4. Further Mechanistic Elucidation of Compound 6 
     Work with compounds 1-6 was already in progress when the author joined the Arambula 
Research Group. The IC50 values of these compounds had been established at the University of 
Texas, and a flow cytometer had already been used to measure intracellular ROS levels in cells 
exposed to each of Auranofin and compounds 2-6. Enzymatic activity had also been measured 
for these compounds. Because the behavior of cells exposed to these compounds has been 
established by the group, these compounds are used for training purposes for new members of 
the Arambula Research Group. This also serves to verify the replicability of the work done with 
these compounds, as the new members of the group are in Georgia, not Texas.  
4.1 Zinc Synergy Study 
     Prior work with ferrocene-functionalized Au-NHC 6 provided evidence that bimodal pathway 
targeting resulted in greater accentuation of exogenous ROS and increased potency to inhibit cell 
proliferation. It was also found that A549 cells exposed to compound 6 had higher levels of 
intracellular chelatable zinc. To this end, cell proliferation assays were conducted on cells from 
the same original flask of A549 that were dosed with identical concentrations of drug. The only 
difference between the two plates for each drug would be that one plate per drug would also be 
treated with 100 µM zinc acetate. After a 3-day incubation, both plates would be dyed with the 
same dye solution, and the data would be collected and analyzed. The IC50 values from each 
plate would then be statistically evaluated to determine if they were statistically different. In 
these experiments, Auranofin displayed an IC50 value of 1.01 +/- 0.17 µM in A549 cells. The 
average IC50 of Auranofin with 100µM zinc acetate was 0.52 +/- 0.07 µM in A549 cells. When 
submitted to t-test analysis in GraphPad, the p-value was 0.0271, which is statistically 
significant. However, when the IC50 values of the Auranofin with 100µM zinc acetate are 
analyzed with the IC50 values of every run with Auranofin alone, the difference becomes 
insignificant (p=0.0604), as the average for every run of Auranofin alone in A549 is 0.92 +/- 
0.16 µM. The average IC50 value for compound 6 in the presence of 100 µM zinc acetate was 
0.127 +/- 0.026 µM, which is not statistically different from the average IC50 value of compound 
6 without zinc 0.159 +/- 0.017 µM (p=0.3174).  
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Table 6. P-values of IC50 values from the zinc synergy study. Values <0.05 are significant. 
 Auranofin 6 
Auranofin + 100 µM ZnOAc 0.0271 0.0003 
6 + 100 µM ZnOAc 0.0009 0.3174 
 
Figure 29. Cell proliferation curves for A549 cells treated with Auranofin alone, and 
Auranofin in the presence of 100 µM ZnOAc for three days. 
 
Figure 30. Cell proliferation curves for A549 cells treated with compound 6 alone, and 
compound 6 in the presence of 100 µM ZnOAc for three days. 
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Table 7. Average IC50 values of A549  
Compound(s) Average IC50 in A549 (µM) Standard Error 
6 0.14 0.03 
Auranofin 1.01 0.17 
6 + 100 µM ZnOAc 0.127 0.026 
Auranofin + 100 µM ZnOAc 0.52 0.07 
 
4.2 Potency in Multiple Cell Lines 
      The IC50 values of compound 6 in A2780, A2780CP, and PC-3 were also determined. These 
values were 0.194 +/- 0.002 µM, 0.120 +/- 0.003 µM, and 0.475 +/- 0.079 µM, respectively for a 
3-day drug incubation. Error here is represented as standard error, but was published as standard 
deviation in Arambula et al. 2016. Statistical analysis indicated In A2780, compound 6 has about 
1.5 fold more anti-proliferative activity than cisplatin and 8 fold more potency than carboplatin. 
In A2780CP, this difference is 59 fold for cisplatin and 219 fold for carboplatin.42  There is a 14 
fold difference in the IC50 value for cisplatin in PC-3 relative to that of compound 6.43 Compound 
6 is roughly 190 fold more potent in PC-3 than carboplatin.44 
Table 8. Average IC50 values of compound 6 in other cell lines and comparison with 
literature values for Cisplatin and Carboplatin. 
Cell Line Average IC50 of 
Compound 6
 
(µM) 
Average IC50 of 
Cisplatin (µM) 
Average IC50 of 
Carboplatin 
(µM) 
A2780 0.194 +/- 0.002 0.31 +/- 0.0642 1.6 +/- 0.342 
A2780CP 0.120 +/- 0.003 7.1 +/- 0.0942 26.3 +/- 4.142 
PC-3 0.475 +/- 0.079 6.643 9044 
  
4.3 RNA Isolation for Microarray and Verification of RNA Quality 
     The QIAgen Protocol for RNA Isolation consistently yielded large quantities of high-purity 
RNA, as determined by NanoDrop. RNA purity and integrity was visually verified after isolation 
by gel electrophoresis. Wells that contain genomic DNA will have bands of high molecular 
weight near the wells, as the DNA will not migrate far. Absence of these bands indicates that the 
RNA is free of intact genomic DNA. MicroRNA will appear as a faint band or smudge near the 
far end of the gel, unless it is run completely off the gel. Ribosomal RNA subunits that are intact 
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will form two distinct bands near the middle of the gel. These bands will be the 28S (closer to the 
wells) and 18S (closer to the far end of the gel) ribosomal subunits. If these appear as smudges 
instead of distinct bands, the RNA has been sheared during extraction. Ideally, isolated RNA 
should be intact, with no DNA contamination or smudging, and have only the bands mentioned 
above.45–47 Our gel shows that the RNA isolated by the QIAgen Protocol meets these criteria for 
purity and integrity (Figures 31 and 32). 
 
Figure 31. Agarose gel dyed with ethidium bromide and transilluminated with UV light to 
show RNA sample quality.  
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Figure 32. Agarose gel dyed with ethidium bromide and transilluminated with UV light to 
show RNA sample quality. In the red oval, the absence of genomic DNA can be observed. 
In the yellow oval, the presence of the 28S ribosomal subunit can be observed. In the blue 
oval, the presence of the 18S ribosomal subunit can be observed. 
4.4 Microarray 
     Biostatistical analysis (provided by the University of Florida Interdisciplinary Center for 
Biotechnology Research) yielded 700 differentially-expressed genes in cells treated with 2.5 µM 
6 relative to untreated cells. Table 9 shows some of the most note-worthy and most 
differentially-expressed genes from this group. Several up-regulated genes related to oxidative 
stress (HMOX1, MT1G, MT1B, MT1H, XBP1, and OSGIN1) were identified in cells treated 
with 6 relative to cells treated only with vehicle. In addition, several genes related to the 
Response to ER Stress pathway (CHAC1, DDIT3, TRIB3, ASNS, HERPUD1, ERN1, ATF3, 
AARS, CXCL8, and HSPA5) were also identified. Another ER-stress response pathway, the 
Unfolded Protein Response, was upregulated, as well (DDIT3, ASNS, HERPUD1, ERN1, ATF3, 
AARS, CXCL8, and HSPA5). This result is thought significant, as compounds with similar 
modes of action to compound 6 are known to localize in the mitochondria.48 In the case of cells 
treated with compound 6, no mitochondria-related gene expression was identified. This data 
leads us to believe that compound 6 localizes in the endoplasmic reticulum. This prompted the 
desire for a study of intracellular localization of compound 6. As seen in Table 10, several genes 
associated with tRNA synthesis were also differentially expressed between treated and untreated 
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cells. Several genes related to the p53 pathway and apoptotic signaling were also differentially 
expressed between treated and untreated cells, as seen in Table 11. 
Table 9. Differentially expressed genes between cells treated with 6 and untreated cells. FC 
is fold change. 
Gene 
ID 
Gene 
symbol Gene Description FC P-value 
79094 CHAC1 ChaC, cation transport regulator homolog 1 5.56 1.19205E-07 
1649 DDIT3 DNA-damage-inducible transcript 3 4.43 4.30297E-09 
57761 TRIB3 tribbles pseudokinase 3 (TRIB3) 4.41 6.5417E-08 
440 ASNS asparagine synthetase (glutamine-hydrolyzing) 3.94 3.28201E-08 
27063 ANKRD1 ankyrin repeat domain 1 (cardiac muscle) 3.90 0.000102275 
7779 SLC30A1 solute carrier family 30 (zinc transporter) 2.86 0.002992119 
23645 PPP1R15A protein phosphatase 1, regulatory subunit 15A 2.79 7.03697E-07 
7436 VLDLR very low density lipoprotein receptor 2.56 3.7443E-06 
9709 HERPUD1 homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain 2.48 2.53382E-07 
2081 ERN1 endoplasmic reticulum to nucleus signaling 1 2.44 1.02427E-06 
3162 HMOX1 heme oxygenase (decycling) 1 2.41 6.63288E-05 
4495 MT1G metallothionein 1G 2.24 0.034444693 
467 ATF3 activating transcription factor 3 2.10 1.231E-06 
16 AARS alanyl-tRNA synthetase 2.03 3.39778E-06 
2920 CXCL2 chemokine (C-X-C motif) ligand 2 1.93 0.00014337 
4490 MT1B metallothionein 1B 1.92 0.032952383 
3576 CXCL8 chemokine (C-X-C motif) ligand 8 1.92 1.10178E-05 
7494 XBP1 X-box binding protein 1 1.87 3.60972E-05 
4496 MT1H metallothionein 1H 1.77 0.025658976 
3311 HSPA7 heat shock 70kDa protein 7 1.63 0.008645638 
6782 HSPA13 heat shock protein 70kDa family, member 13 1.54 0.001471724 
3309 HSPA5 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) 1.51 2.83009E-05 
29948 OSGIN1 oxidative stress induced growth inhibitor 1 1.48 0.000144965 
57181 SLC39A10 solute carrier family 39 (zinc transporter), member 10 0.63 0.016893383 
3306 HSPA2 heat shock 70kDa protein 2 0.56 1.49155E-05 
6347 CCL2 chemokine (C-C motif) 0.39 1.53404E-05 
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Table 10. Differentially expressed genes between cells treated with 6 and untreated cells 
that are associated with tRNA synthesis. FC is fold change. 
Gene Symbol Gene Description FC P-value 
ASNS asparagine synthetase 1.980 3.28201E-08 
GARS glycyl-tRNA synthetase 1.180 1.23327E-06 
CARS cysteinyl-tRNA synthetase 1.148 2.65564E-07 
AARS alanyl-tRNA synthetase 1.025 3.39778E-06 
SARS seryl-tRNA synthetase 0.947 5.4855E-06 
MARS methionyl-tRNA synthetase 0.901 6.87998E-06 
YARS tyrosyl-tRNA synthetase 0.813 6.23673E-06 
TARS threonyl-tRNA synthetase 0.602 7.61352E-05 
EPRS glutamyl-prolyl-tRNA synthetase 0.580 0.001311123 
NARS asparaginyl-tRNA synthetase 0.568 0.000213934 
WARS tryptophanyl-tRNA synthetase 0.568 0.000373972 
IARS isoleucyl-tRNA synthetase 0.524 4.26376E-05 
 
Table 11. Cell death-associated genes differentially expressed between treated and 
untreated cells. FC is fold change. 
Gene 
Symbol Gene Description FC P-value 
GADD45A growth arrest and DNA-damage-inducible, alpha 1.000 3.37849E-05 
TNFRSF10B tumor necrosis factor receptor superfamily, member 10b, transcript variant 1 0.645 1.19697E-05 
SERPINE1 serpin peptidase inhibitor, clade E 0.668 0.027882965 
CCNB1 cyclin B1 interacting protein 1, E3 ubiquitin protein ligase, transcript variant 1 0.562 5.26928E-05 
IRAK2 interleukin-1 receptor-associated kinase 2 0.873 5.07967E-05 
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4.5 Xenografts 
Xenografts were prepared of A549 in Danio rerio larvae (hatched zebrafish young). As seen in 
Figure 33, compound 6 was capable of killing the cancerous cells without killing the larvae. 
Figure 33. Microscopic images of labelled A549 cells in Danio rerio larvae. Figure courtesy 
of Dr. Sittaramane. 
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Chapter 5. Discussion 
     Complex 9 was designed to assess whether the targeting of a network hub (TrxR) in 
conjunction with an increase of network stress (higher levels of ROS) would lead to a greater 
alteration in a phenotypic response (cell growth) (cf. Figure 8). The Au(I)-NHC and 
naphthoquinone moieties were specifically chosen to 1) inhibit TrxR via irreversible binding of 
Au(I) to the selenothiol-containing active site and 2) accentuate ROS via redox cycling of the 
naphthoquinone moieties, both within a single molecule. Regarding the ability to inhibit cell 
proliferation, a substantial increase in potency was observed when considering whole complex 9 
compared to Auranofin (23-fold), 8 (~14-fold), or 4 (~10-fold). The latter two compounds (8, 4) 
provide examples of the individual components of complex 9. More interestingly, the potency 
difference between 9 and treatments consisting of an equimolar ratio of 8 and 4 (mimicking that 
within 9) suggests a potential synergistic effect when the active moieties are conjugated to create 
a single complex. The ability to inhibit cell proliferation can often be explained by better 
understanding cell uptake profiles and potential interactions with extracellular proteins. In 
consideration of this, it was found by ICP-MS detection of Au that NHC complexes 9 and 4 enter 
the cell to the same extent, and provided no evidence of interaction with serum proteins. This is 
in stark contrast to Auranofin, a complex known to bind serum proteins and presumed to enter 
the cell via protein-assisted uptake; both of which were corroborated by ICP-MS studies reported 
herein (cf. Figures 15 and 16). 
     In regards to 9 being able to accentuate intracellular ROS levels, flow cytometry studies in 
A549 cells indicated a dose-responsive increase in ROS, providing a 27-fold increase at 2.5 µM 
9 after a 6-hour incubation. Similar to the cell proliferation studies, the phenotypic 
alteration/response of the whole complex (i.e. 9) was greater than the individual components (i.e. 
8, 4) when compared at all complex concentrations. However, the ROS accentuation difference 
between 9 and treatments consisting of an equimolar ratio of 8 and 4 (mimicking that within 9) 
were statistically similar indicating the lack of synergy regarding the alteration of the ROS 
phenotype. The inconsistency of synergy between the growth and ROS phenotypes is suggestive 
of additional mechanisms of action not known at this juncture. 
     As would be expected from the proposed dual targeting mode of action, complex 9 did inhibit 
TrxR activity to a greater extent than its individual parts (i.e. 8, 4). At low compound 
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concentration, 9 was found to inhibit TrxR to the same extent as Auranofin (cf. Figure 19), a 
result not seen in our previous reports.31 Live cell treatments with a cocktail of 8+4 provided 
similar TrxR inhibition to that of complex 9. This evidence suggests that the increased TrxR 
inhibition by 9 is due to the presence of the naphthoquinone moieties and not due to potential 
differences in Au-carbene strengths between 9 and 4. 
     In considering the design of 9, large conjugated multi-ring systems are suggestive of potential 
interactions with nucleic acid based biomolecules. Doxorubicin, a conjugated anthracycline 
possessing a quinone moiety, is such an example, as its accepted anti-cancer mechanism of 
action is the inhibition of topoisomerase II via DNA intercalation. However, in healthy cardiac 
tissue, it has been established that Doxorubicin induces cellular stress and dose-limiting toxicity 
via mitochondrial ROS accentuation.49–51 This duplicity is suggestive that similar conjugated 
systems (such as that seen on the naphthoquinone moieties of 9 and 8) may elicit a similar 
mechanism of action. To this effect, thermal denaturation studies with short DNA duplexes were 
done to elucidate such a mechanism. Significant DNA stabilization by Doxorubicin was evident, 
however no thermal stabilization of DNA by 9 or 8 was observed under the study conditions. 
This suggests no interaction with DNA or other nucleic acid based biomolecules with 9 or 8 
(Figure 28). Despite the potential differences in biological targets, treatment with complex 9 was 
found to induce the formation of two positive Annexin-V populations (+PI, -PI), which is 
indicative of cell death via a controlled apoptotic mechanism (cf. Figure 25). This observation 
was further corroborated by comparison to results with Doxorubicin known to induce apoptosis 
(cf. Figures 26 and 27). 
     To further explore the utility of complex 9 and naphthoquinone 8, their ability to inhibit cell 
proliferation was evaluated within a limited panel of cancer cell lines: PC-3 prostate (p53 null), 
A2780 ovarian (wt-p53, platinum sensitive), and A2780CP (wt-p53, isogenic partner to A2780 
displaying multidrug resistance (MDR)). From these results, it should be noted that complex 9 
provided enhanced potency within A2780, whereas no significant potency differences were 
observed between A549, A2780CP, or PC-3. Regarding naphthoquinone 8, stronger potency was 
observed in A2780 and PC-3 relative to A2780CP and A549. These trends provide a unique 
pharmacological profile that warrants further exploration.  
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     To further elucidate the mechanism of 6, RNA microarray gene expression was conducted. Of 
the 279 genes that were differentially expressed, a significant number were associated with 
apoptosis and cell cycle arrest, as might be expected. Gene Ontology (GO) analyses of the 
transcripts that were differentially-regulated in response to exposure to compound 6 were 
performed to investigate cellular responses to this complex. Intriguingly, ER stress and oxidative 
stress response genes were found to be enriched in this analysis. These data, coupled with the 
differential expression of HMOX1 (containing an antioxidant response element in its promoter) 
and OSGIN1 (an oxidative response protein that regulates cell death), were taken as an 
indication that the oxidative stress induced by 6 results in ER stress. The subsequent 
upregulation of SLC30A1, downregulation of SLC39A10 (both zinc transporters) and 
upregulation of multiple Metallothioneins are thought to reflect a response to ROS stress, since 
they serve to attenuate an increase in intracellular zinc concentrations. The role free intracellular 
(non-protein bound) zinc plays in regulating cellular functions is of considerable relevance to 
cancer. For example, increased free zinc concentration has been proposed to stabilize hypoxia-
inducible factor-1 (HIF-1) and thus influence processes such as glycolysis, apoptosis, and 
angiogenesis.52 Moreover, free zinc inhibits thioredoxin reductase,53 a key mediator in the 
cellular response to oxidative stress that is frequently overexpressed in cancer.10,54–59 
     The scope and activity of gold complex 6 was further evaluated within a limited panel of 
cancer cell lines (PC-3 prostate (p53 null), A27780 ovarian (wt-p53 platinum sensitive), and 
A2780CP (wt-p53 isogenic partner to A2780 displaying multidrug resistance (MDR)) displaying 
varying p53 status and drug resistance. From these results, it should be noted that there was no 
observed resistance in A2780CP relative A2780 cell lines. This result is considered significant in 
that small molecular platinum-containing species often display 2-27 fold resistance between this 
isogenic pair.3,42 
     Compounds 6 and 9 were shown to be lethal to Danio rerio embryos at all concentrations of 
10nM or higher. Further studies into intracellular localization of 6 and possibly 9 by confocal 
microscopy and/or mitochondrial extraction are planned. Xenografts of A549 and PC-3 into 
Danio rerio embryos to study the in vivo effects of compounds 6 and 9 are in progress, but not 
yet completed. Preliminary results suggest that compound 6 is effectively killing the xenografted 
cells without killing the host. 
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     At 2.5 µM, all of the experimental compounds studied except compound 11 were shown to 
disrupt antioxidant activity by protein inhibition and increase intracellular ROS. The 
experimental compounds were also shown to have high anticancer potency by the MTT assay. 
These results are supportive of the hypothesis that multimodal pathway targeting will result in 
enhancement in phenotypic alterations that are controlled by said pathway.  
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Chapter 6. Materials and Methods 
6.1 Materials 
     Cell culture media consisted of RPMI 1640 with 2 mM glutamine and 25 mM HEPES 
(Corning 10041cv), with 10% heat-inactivated fetal bovine serum (RMBIO FBS-BBT) and 1X 
penicillin-streptomycin (Sigma p4333). Unless otherwise noted, incubators were set to 37 °C and 
5% CO2. Trypsin (HyClone SH30236.01) and 1X Phosphate Buffered Saline (HyClone 
SH30258.02, diluted in autoclaved deionized water) were used for general cell line maintenance 
and harvesting. Cell lines were obtained from the ATCC (A549 and PC-3) and Prof. Zahid 
Siddik at the M.D. Anderson Cancer Center (A2780 and A2780CP). Cell culture plastic ware 
consisted of generic T-75 flasks, treated 6-well plates, treated 96-well plates, large treated dishes, 
and cell scrapers (Fisher 353085).  
     Compounds 1-11 were synthesized by Dr. Kuppuswamy Arumugam at Wright State 
University.31 Auranofin (Tocris Bioscience 4600) was used as a control in enzymatic studies. 
Stock solutions of complexes 1-11 and Auranofin were made in DMSO (2.5 mM-10 mM, 
depending on the compound and its solubility). Doxorubicin (Tocris Bioscience 2252) was used 
as a control in cell proliferation assays and intracellular ROS studies, and stock solutions were 5 
mM in DMSO. Cisplatin (Acros Organics 193762500) stock solutions were 5 mM in 100 mM 
NaCl (Carolina 88-8880) in deionized water. Cisplatin and zinc acetate stock solutions were then 
sterile filtered using a 0.2 µm syringe filter (Fisher 973019). Zinc acetate (Baker 4296) was used 
for zinc synergy studies, and its stock solutions were 5 mM in autoclaved deionized water.  
     Thiazolyl blue tetrazolium bromide (Alfa Aesar L11939) was used for cell proliferation 
assays. A Molecular Devices SpectraMax 190 UV-vis plate reader was used to record the 
absorbance values for the MTT cell proliferation assay, the lipoate reduction assay for 
Thioredoxin Reductase activity, and the Modified Lowry assay. 
     Trace Metal Grade acids for use with the ICP-MS were HCl (Fisher A508-4) and HNO3 
(Sigma 225711-475mL). Diluent for samples and standards run on the ICP-MS was a 3% HCl 
solution made with the Trace Metal Grade HCl and autoclaved deionized water. The Inductively-
Coupled Plasma Mass Spectrometer used was a Perkin Elmer NexION 300X set to detect gold at 
197 m/z. Gold concentrations were quantified using the linear range of a standard curve 
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generated by serial dilution of an ICP-MS gold standard (Ricca MSAU1KH-100) in 3% HCl. 
Values were then normalized to protein content as determined using a Modified Lowry Protein 
Assay Kit (Thermo 23240) and known concentrations of bovine serum albumin (Fisher 9048-46-
8). The Lowry Assays were performed in round bottomed 96-well clear plates (Fisher 
12565500). The stir table used for mixing Lowry samples was a Lab-Line Instruments, Inc. 3520 
Orbit Shaker. The settings used were the maximum settings that allowed the plate to remain on 
the table. 
     Fetal bovine serum (HyClone SH30910.02) that was not heat-inactivated was used for protein 
binding studies after being warmed to roughly 37 °C. 
     The activity of Thioredoxin Reductase was monitored in live cells using a solution of lipoate 
(Tokyo Chemical Industry Co., Ltd. L0207) and DTNB (Acros Organics 117540050) in 1X 
HBSS (Life tech 14025-092). If insufficient lipoate was dissolved, this will become evident by 
curvature of the graph of the normalized lipoate reduction over time after reagent introduction. 
This graph should be practically linear for all treatments over the entire course of the experiment. 
It can be seen in Figures 19, 20, 22, 23, 33, 34, 45, and 46 that these graphs were linear for all 
treatments tested in our lab. 
     The QIAgen Protocol for RNA Isolation utilized a QIAgen RNeasy Plus Universal Mini Kit. 
RNA concentrations were determined using a Thermo Scientific NanoDrop 2000c 
Spectrophotometer. RNA quality was visually verified using ethidium bromide and an agarose 
gel. Agarose (IBI Molecular Biology Certified IB70070) was dissolved in autoclaved 1X TAE 
buffer (diluted from BIORAD 50X TAE buffer), spiked with 12 µL of 10 mg/mL ethidium 
bromide, and cast using a Fisher FB-SB-710 gel electrophoresis chamber. The ladder used was a 
Thermo SM1331 Generuler 1kb Plus DNA Ladder.    
     For the flow cytometry, CM-H2DCFDA (Lifetech C6827) was used for the determination of 
relative intracellular ROS, and propidium iodide (Chemodex P0023) was used to exclude dead 
cells from the population of interest. An FITC Annexin V Apoptosis Detection Kit (BD 
Biosciences 556547) was used for determining whether the compounds were acting by apoptosis 
or necrosis. The flow cytometer used was a Millipore Guava easyCyte8 working in conjunction 
with Guava inCyte software. 
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     Thermal melt data was obtained using duplex DNA from IDT with complementary sequences 
5’CCGCAGCCA3’ and 5’TGGCTGCGG3’. The instrument used was a Shimadzu 2600 UV-vis 
spectrophotometer equipped with an 8-cell microcell (b= 1.0 cm, 130 µL total volume) and a 
thermal melt apparatus. 
     A549 and PC-3 cells were prepared for injections into Danio rerio embryos to form a 
xenograft model in which to study the in vivo effects of compounds 6 and 9 on tumors formed by 
these cell lines. RPMI 1640 (Just Media) was used during the dye process. The dye used to track 
the cells once in the fish was Vybrant DiI Cell Labeling Solution (LifeTech V22889). 
6.2 Assay Overview and Design 
     Several well-established assays were used to evaluate the biological activity of our 
compounds in cancer cell models. The MTT assay is a colorimetric assay in which a water-
soluble tetrazolium dye is introduced to cells, and allowed to incubate for 4 hours. During the 
incubation, the thiazolyl blue tetrazolium bromide (yellow) enters the cell. If the cells are alive 
and actively proliferating, the mitochondrial enzymes of the cell will react with the dye to form 
purple water-insoluble formazan crystals. The crystals remain in the cell and can be observed 
microscopically at the end of the incubation. After removal of the liquid in the plate that the 
experiment was conducted in, the cells and crystals can be solubilized in DMSO, and the 
absorbance at 570 nm can be recorded. This can then be used to determine relatively what 
percentage of cells in each treatment group was actively proliferating. The data can be graphed 
as percent cell proliferation vs. concentration of compound in the well, and then fit with curve-
fitting software to determine the IC50 of the compound in the cell line under those conditions. 
The IC50 value is a measure of the anti-proliferative potency of the compound. It is the 
concentration at which half of the cells are proliferating, and half of them are not. Important 
variables to note when comparing IC50 values are the length of cell exposure to the compound, 
the cell line used, and literature values of other compounds under the same conditions.20,61,62  
     The lipoate reduction assay is commonly used to measure the activity of the antioxidant 
enzyme thioredoxin reductase in vitro. It offers a way of assessing the effects of a compound on 
the upper threshold of ROS homeostasis in the cell. After incubating the cells in the desired 
concentrations of compound for a few hours, the media is removed and replaced with a solution 
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of lipoate and DTNB reagent in isotonic buffer. The absorbance of the wells at 405 nm is then 
observed periodically for several hours. During this time, the lipoate enters the cells. Intracellular 
thioredoxin reductase then reduces the lipoate, forming dihydrolipoate. Dihydrolipoate is then 
excreted from the cell, where it can interact with extracellular DTNB, causing a color change 
from a pale yellow to a much more intense yellow.6,9 The data from this can be graphed in many 
ways, which will be discussed later.  
      Intracellular levels of ROS can be quantified by flow cytometric analysis with the help of 
CM-H2DCFDA and propidium iodide (PI). CM-H2DCFDA is a fluorescein-based dye that has 
been modified with acetate groups, such that the dye will not react with reactive oxygen species 
found outside the cell. After entering the cell, the acetate groups are cleaved by intracellular 
enzymes, allowing the dye to react with intracellular reactive oxygen species. The product of this 
reaction fluoresces green.5 Propidium iodide is a fluorescent dye that cannot permeate the cell 
membrane. However, propidium iodide intercalates with nucleic acids, which changes its 
excitation and emission wavelengths. As a cell dies, the membrane becomes permeable to the 
propidium iodide, and other dyes used to indicate cell death. This allows the researcher to 
exclude dead cells from the population of cells with high green fluorescence, so that only live 
cells are studied.63     
     A microarray was used to measure differential gene expression in treated and untreated cells. 
This technique is well-established, but costly. In the procedure, live cells are lysed, and their 
mRNA is isolated. The purity, concentration, and quality of the mRNA is assessed, and then 
hybridized with a fluorescent dye. Samples from treated cells are hybridized with one dye, while 
samples from untreated cells are hybridized with another dye (usually, one is red, and the other is 
green). The samples are then washed over a chip with affixed DNA sequences that correspond to 
specific genes. If the mRNA encounters a complementary DNA sequence, it will form a duplex. 
Excess mRNA is then washed off of the chip, and the fluorescence of both dyes is recorded for 
each position on the chip. The data is run through a computer, which is programmed to know 
what gene was encoded at each position. A biostatistician can interpret the data and report what 
genes are being expressed differentially and what the difference in expression is between the two 
groups.64 
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6.3 Cell Proliferation by MTT Assay 
     Cells were harvested and seeded into 96-well culture plates (Costar 07-200-90) in 100 µL of 
culture media. They were allowed to incubate overnight at 37 °C in the presence of 5% CO2. 
A549 was seeded at a density of 1000 cells/well, A2780 at 2500 cells/well, A2780CP at 3000 
cells/well, and PC-3 at 2000 cells/well. The next day, appropriate serial dilutions of drug stocks 
in culture media were made. 100 µL of the appropriate solution was then added to each well of 
the 96-well plate. The final concentration of DMSO in these solutions was not permitted to 
exceed 10% of the solution. Cells were then placed into the incubator for three days, before 
being dyed with 50 µL/well of 3 mg/mL MTT dye in serum-free RPMI 1640 and incubated for 
another 4 hours. The liquid was then removed from the plates by vacuum aspiration. The 
remaining cells and formazan crystals were dissolved in 50 µL/well DMSO. The absorbance of 
the wells at 570 nm was then recorded using a Molecular Devices SpectraMax 190 UV-vis plate 
reader. The average absorbance of the wells with dead cells as determined by microscopic 
observation was subtracted from the average absorbance of all other treatments. The average 
absorbance of wells with live, happily proliferating cells was defined as 100% cell proliferation. 
The average percent cell proliferation per treatment was then determined, and the IC50 values 
were determined using the non-linear curve-fitting tool on Origin. IC50 values were compared on 
GraphPad by the unpaired t-test, with a confidence interval of 95%. A significant difference in 
values is shown by a p-value less than 0.05 in this confidence interval. A p-value of 0.01 or 
below is seen as a much more significant difference, with a much higher confidence interval. 
6.4 Cellular Uptake as Determined by Lowry Assay and ICP-MS 
     Cells were grown up to 70-80% confluence in T-75 cell culture flasks (Thermo 130190). 
Cells were then washed with 8 mL 1X warm PBS. 2 mL 1X PBS was then added to each flask, 
and the cells were removed by scraping. Each cell suspension was then pipetted into a clean, 
labeled 15 mL centrifuge tube (Thermo 339650). Cells were pelleted by centrifuging at 1000 
rpm for 5 minutes in an Eppendorf 5804 with a swing-bucket rotor. The supernatant was 
removed by vacuum aspiration, and the pellet was resuspended in 50 µL autoclaved deionized 
water. Suspension/lysates were then kept at -80 °C. After thawing, the lysates were then 
sonicated using a Branson Digital Sonifier, and 5 µL aliquots were taken for determination of 
protein content of the sample. Lysates were digested with 80 µL aqua regia and heated to 65 °C 
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for one hour. Digested lysates were diluted with 4 mL 3% Trace Metal Grade HCl and gold 
content was measured by ICP-MS.  
     The Modified Lowry Assay was used to determine the protein content of each sample for 
normalization purposes. The standard curve for each run was made from a 2-fold serial dilution 
of fresh 5 mg/mL BSA solution. Aliquots were diluted to within the linear range of the standard 
curve using autoclaved DI water, and subjected to the Modified Lowry Assay in a 96-well plate. 
Each well contained 10 µL of sample, 50 µL of Modified Lowry Reagent, and 5 µL of 1N Folin-
Ciocalteau Reagent.  All other aspects of the procedure were as detailed in the microplate 
procedure instructions that come with the kit.65 
6.5 Serum Protein Binding Study 
     The binding of gold from each compound to proteins in fetal bovine serum were observed 
during a time-dependent study. A 25 µM solution of each compound in 3 mL warm FBS was 
made. The solutions were kept at 37 °C. Over time, 100 µL aliquots of each solution were taken 
and precipitated into 400 µL cold methanol. Precipitated aliquots were stored at -80 °C. The 
methanolic suspensions were then centrifuged at 13000 rcf for 5 minutes in an Edvotek 
microcentrifuge. The supernatants were pipetted into new microcentrifuge tubes. Samples were 
prepared for ICP-MS by adding 200 µL supernatant from each sample to 2 mL 3% Trace Metal 
Grade HCl. Time points were at addition of compound (T0), 4, 6.25, 9.75, 12, 24, 48, 72, and 
100 hours.  
6.6 Determination of Intracellular ROS 
     In Texas, 1 million cells/well of A549 were seeded into a 6-well plate in culture media and 
allowed to adjust overnight in the incubator. The next day, cells were treated with 0.625-2.5 µM 
compound. Control cells were treated with DMSO in culture media. After incubating for 6 hours, 
the liquid was removed by vacuum aspiration and the cells were washed with PBS. Cells were 
then treated with 250 µL trypsin and incubated for 5-15 minutes, after which they were collected 
into a tube. Cells were centrifuged for 3 minutes at 300 rcf at 5 °C. The supernatant was removed 
by vacuum aspiration. Then, the cells were washed twice with cold PBS, and centrifuged again at 
300 rcf for 3 minutes at 5 °C. The supernatant was discarded again. The cells were resuspended 
at a density of 1 million cells/mL in fresh 2 µM CM-H2DCFDA in PBS. After this, they were 
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incubated in the dark for 15 minutes, and centrifuged again to pellet the cells. Then, the 
supernatant was discarded, the cells were washed with 2 mL of PBS, and the cells were 
resuspended in 2 µg/mL propidium iodide in PBS at a density of 0.5 million cells/mL. Controls 
included cells dyed only with propidium iodide, cells dyed only with CM-H2DCFDA, and 
unstained cells. Each sample was then pipetted into 1 well of a 96-well plate, and submitted to 
FACS analysis.  
6.7 Inhibition of Intracellular Thioredoxin Reductase by Lipoate Reduction Assay 
     Cells were harvested and seeded at a density of 10000 cells/well A549 in 96-well culture 
plates. They were then incubated overnight at 37 °C and 5% CO2. The next day, appropriate 
serial dilutions of drug stock in culture media were performed, and 100 µL of the appropriate 
solution were added to each well. Cells were returned to the incubator for 6 hours. Afterwards, 
the liquid was then removed from each well by vacuum aspiration and replaced by 100 µL of 5 
mM lipoate and 1 mM DTNB in HBSS. The absorbance of each well at 605 nm was recorded 
immediately and once every 20 minutes for three hours. Plates were covered with aluminum foil 
between readings. The average absorbance of each treatment at T0 was subtracted from the 
average absorbance of that same treatment at all other time points. The average absorbance of the 
control wells at 180 minutes after addition of the lipoate-DTNB reagent was defined as 1, and all 
other data points were normalized to that value. Data is presented by dose of compound, by the 
compound used over all doses used, and by compound used over time after addition of the 
lipoate-DTNB reagent, along with standard error. 
6.8 Determination of Cell Death Pathway by FITC Annexin V 
     An FITC Annexin-V Apoptosis Detection Kit from BD Biosciences was used to determine 
whether cells exposed to various compounds were dying by apoptotic pathways or by necrosis. 
In Texas, 200,000-300,000 cells of A549 were seeded into each well of a 6-well plate in culture 
media and allowed to adjust overnight in the incubator. The next day, cells were treated with 
1.25-20 µM drug in culture media and incubated for 24 hours. Control cells were treated with 
DMSO in culture media. After the incubation, the media from each well was collected. The cells 
were washed with PBS, and the wash was also collected. Half-strength trypsin in PBS was 
introduced to the cells, and the cells were incubated for 2 minutes. The loosened cells were 
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pooled with their respective collected media and PBS wash, and then centrifuged at 300 rcf for 3 
minutes. The supernatant was discarded, and the cells were washed twice with cold PBS. The 
cells were centrifuged again at 300 rcf for 3 minutes. The supernatant was discarded, and the 
cells were resuspended in Annexin V binding buffer at a density of 1 million cells/mL. A 100 µL 
aliquot of each sample was then placed into a new microcentrifuge tube. Each sample was then 
treated with 5 µL Annexin V and 50 µg/mL propidium iodide solution. Controls included 
unstained cells, cells stained with just Annexin V, and cells stained with just propidium iodide. 
Cells were incubated in the dark for 15 minutes at ambient temperature, and then diluted with 
200 µL Annexin V binding buffer. After this, each sample was placed into 1 well of a 96-well 
plate and submitted to FACS analysis. 
6.9 DNA Binding as Determined by Thermal Denaturation 
     The ability of doxorubicin, compound 8, and compound 9 to alter the stability of a DNA 
duplex was determined by thermal denaturation performed by Zarana Patel. Stock solutions of 
1.6 mM DNA were made in 1X TE buffer and stored at 5 °C. When duplex DNA was needed, 
equimolar amounts of the complementary strands were mixed and incubated at 95 °C for 5 
minutes, then chilled on ice. Tubes were then centrifuged to collect any condensate. The 
resulting solution was aliquoted into microcentrifuge tubes, and 1 molar equivalent of compound 
was added to each tube. Each tube then received 12 µL 1 mM EDTA, 12 µL 100 mM NaCl, 12 
µL 20 mM MOPS buffer pH 7.4, and sufficient diluent for a final volume of 120 µL/sample. 
This yielded a final DNA and compound concentration of 5 µM. Each sample was placed into 
one well of the 8-microcell cuvette, and run through the Shimadzu 2600 UV-vis thermal melt 
apparatus. The samples were heated to 95 °C from 20 °C at 1 °C/minute. The resulting data was 
then run through Origin (a program from MicroCal) to determine the maximum of the first 
derivative of the curve. 
6.10 RNA Isolation for Microarray and Verification of RNA Quality 
     The QIAgen Protocol was used to isolate RNA from untreated cells and cells treated with 
compound 6 prior to use for microarray. About 5 million A549 cells in 11 mL of culture media 
were seeded into each of two large treated culture dishes per replicate. For each replicate, cells 
used were from the same original flask and passage. The cells were then returned to the 
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incubator and allowed to sit overnight. The next morning, control cells were given 11 mL more 
culture media, while treated cells were given 11 mL of 5 µM compound 6 in culture media, for a 
final concentration of 2.5 µM. After incubating for 6 hours, the liquid in each dish was removed 
by vacuum aspiration. The cells were then washed with 5 mL warm PBS, then incubated with 
2.5 mL trypsin for 5 minutes. The trypsin was then quenched with 10mL culture media, and the 
cells were collected into centrifuge tubes by pipetting. Cells were centrifuged at 1000 rpm for 5 
minutes in an Eppendorf 5804 with a swing-bucket rotor, and then the supernatant was removed 
by vacuum aspiration. Each pellet was resuspended in 380 µL PBS, and then transferred to a 
microcentrifuge tube. Each sample was lysed by adding 900 µL QIAzol Lysis Reagent and 
homogenized by vigorous shaking and vortexing. The QIAgen RNeasy Plus Universal Mini 
Total RNA protocol was then picked up at Step 4.66 Finally, RNA was eluted in a total of 60 µL 
RNase-free water. RNA was stored at -80°C, and RNA concentrations were checked by 
NanoDrop, usually in triplicate. RNA samples that were obtained by the QIAgen Protocol were 
run on a 1% agarose gel spiked with ethidium bromide in 1X TAE buffer at 125 V for 1 hour, 
alongside a dsDNA ladder. About 1400 ng of each sample was run per well, with 1X sample 
loading dye (BIORAD 1660401). Afterwards, the gel was de-stained with water for 10 minutes, 
and photographed with a Kyocera Brigadier while being transilluminated with UV light.  
6.11 Preparation for Microarray 
     After being run on an agarose gel and deemed intact RNA, RNA samples (400 ng + 3 µL) 
were sent to the Interdisciplinary Center for Biotechnology Research at the University of Florida 
for microarray analysis. The microarray used was an Affymetrix GeneChip Human 
Transcriptome 2.0 Array. A biostatistician at UF was paid to further analyze the data. 
6.12 Xenografts in Danio rerio 
     A549 cells were harvested, and aliquots of 1 million cells in suspension were placed into 
microcentrifuge tubes. A total of about 4 million cells were used for each round of the 
experiment. The cells were centrifuged at 500 rcf for 2.5 minutes, and the supernatant was 
discarded. Cells were resuspended in 1 mL of RPMI 1640 per tube. Each tube was then dyed 
with 5 µL DiI solution and mixed well. The cells were then incubated for 15 minutes. After this, 
the tubes were centrifuged at 500 rcf for 2.5 minutes again. The supernatant was discarded, and 
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the cells were resuspended in 200 µL culture media per tube. At this point, cells were walked 
over to Dr. Sittaramane’s lab in the Biological Sciences Building for injection into Danio rerio 
embryos that had been prepared in advance as described in Sittaramane and Abid et al. 2015.67 
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Chapter 7. Conclusion 
     Herein we report that the targeting of an antioxidant network hub (TrxR) results in a greater 
phenotypic alteration (cell proliferation) when combined with a component capable of inducing 
network stress (i.e. accentuation of oxidative stress via redox cycling). The proposed 
incorporation of a redox cycling center within the Au(I)-NHC core provided an enhancement in 
anti-proliferative activity, ROS accentuation, and the inhibition of TrxR activity when compared 
to individual components, thus providing an additional “proof-of-principle” example for the 
suggestion that it is useful to address key cancer-related pathways via multiple modes of 
targeting. Differential gene expression analysis of A549 lung cells treated with ferrocene-
incorporated variants (i.e. 6) suggested that the exogenous ROS accentuation was inducing ER 
Stress and UPR pathways. It has recently been suggested that activation of such stress pathways 
could lead to the immunogenic cell death in vivo.60 Accordingly, further mechanistic studies, 
tests of toxicity and efficacy in mammalian models, as well as efforts to prepare and test second-
generation complexes that are able to accentuate ROS effects via multiple pathways are 
underway. The results of these efforts will be presented in due course. 
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Appendix 
Figure 34. Normalized lipoate reduction with standard error in A549 over 3 hours, after 6 
hours incubation in 2.5 µM compound. 
Figure 35. Normalized lipoate reduction with standard error in A549 over 3 hours, after 6 
hours incubation in 1.25 µM compound. 
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Figure 36. Normalized lipoate reduction and standard error in A549 at 2.5 µM compound, 
180 minutes after addition of lipoate. 
 
 
Figure 37. Normalized lipoate reduction and standard error in A549 at 1.25 µM compound, 
180 minutes after addition of lipoate. 
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Figure 38. Normalized lipoate reduction and standard error in A549 at 0.3125 µM 
compound, 180 minutes after addition of lipoate. 
 
 
Figure 39. Normalized lipoate reduction and standard error in A549 at 0.156 µM 
compound, 180 minutes after addition of lipoate. 
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Figure 40. Normalized lipoate reduction and standard error in A549 at varying 
concentrations of Doxorubicin, 180 minutes after addition of lipoate. 
 
 
Figure 41. Normalized lipoate reduction and standard error in A549 at varying 
concentrations of compound 8, 180 minutes after addition of lipoate. 
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Figure 42. Normalized lipoate reduction and standard error in A549 at varying 
concentrations of compound 4, 180 minutes after addition of lipoate. 
 
 
Figure 43. Normalized lipoate reduction and standard error in A549 at varying 
concentrations of compound 9, 180 minutes after addition of lipoate. 
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Figure 44. Normalized lipoate reduction and standard error in A549 at varying 
concentrations of Auranofin, 180 minutes after addition of lipoate. 
 
 
Figure 45. Normalized lipoate reduction and standard error in A549 at varying 
concentrations of 1:2 4:8 cocktail, 180 minutes after addition of lipoate. 
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Table 12. P-values of t-tests comparing normalized lipoate reduction resulting from 
varying concentrations of compound to that of the same concentration of other compounds. 
Values less than 0.05 are significant. 
Compound [Compound] (µM) Control Dox 8 4 9 Aura 1:2 4:8 
Dox 0.15625 0.0898 --- 0.3529 0.5699 0.0330 0.0436 0.1019 
0.3125 0.1083 --- 0.8214 0.9483 0.1566 0.0114 0.0574 
0.625 0.5855 --- 0.7219 0.4286 0.0021 0.0002 0.0012 
1.25 0.4910 --- 0.4200 0.0105 0.0004 <0.0001 0.0002 
2.5 0.3402 --- <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
5 0.4007 --- 0.0011 0.0002 0.0001 <0.0001 0.0003 
8 0.15625 0.3506 0.3529 --- 0.1420 0.0017 0.0092 0.0080 
0.3125 0.2189 0.8214 --- 0.8792 0.1214 0.0089 0.0484 
0.625 0.1170 0.7219 --- 0.4972 0.0003 <0.0001 0.0002 
1.25 0.6652 0.4200 --- 0.0097 <0.0001 <0.0001 <0.0001 
2.5 <0.0001 <0.0001 --- 0.2151 0.0378 <0.0001 0.0006 
5 <0.0001 0.0011 --- 0.6344 0.0225 0.0046 0.0908 
4 0.15625 0.0204 0.5699 0.1420 --- 0.0824 0.1263 0.2963 
0.3125 0.1276 0.9483 0.8792 --- 0.1491 0.0087 0.0895 
6.25 0.0481 0.4286 0.4972 --- 0.0019 0.0001 0.0013 
1.25 0.0067 0.0105 0.0097 --- 0.2491 0.0140 0.0306 
2.5 <0.0001 <0.0001 0.2151 --- 0.3868 0.0005 0.0069 
5 <0.0001 0.0002 0.6344 --- 0.0031 0.0003 0.0502 
9 0.15625 <0.0001 0.0330 0.0017 0.0824 --- 0.6656 0.0463 
0.3125 0.0012 0.1566 0.1214 0.1491 --- 0.1465 0.2714 
0.625 <0.0001 0.0021 0.0003 0.0019 --- 0.2895 0.1176 
1.25 <0.0001 0.0004 <0.0001 0.2491 --- 0.0186 0.0136 
2.5 <0.0001 <0.0001 0.0378 0.3868 --- 0.0015 0.0151 
5 <0.0001 0.0001 0.0225 0.0031 --- 0.0283 0.2734 
Aura 0.15625 0.0001 0.0436 0.0092 0.1263 0.6656 --- 0.1338 
0.3125 <0.0001 0.0114 0.0089 0.0087 0.1465 --- 0.4080 
0.625 <0.0001 0.0002 <0.0001 0.0001 0.2895 --- 0.2627 
1.25 <0.0001 <0.0001 <0.0001 0.0140 0.0186 --- 0.9995 
2.5 <0.0001 <0.0001 <0.0001 0.0005 0.0015 --- 0.4107 
5 <0.0001 <0.0001 0.0046 0.0003 0.0283 --- 0.0200 
1:2 4:8 0.15625 0.0014 0.1019 0.0080 0.2963 0.0463 0.1338 --- 
0.3125 0.0182 0.0574 0.0484 0.0895 0.2714 0.4080 --- 
0.625 0.0004 0.0012 0.0002 0.0013 0.1176 0.2627 --- 
1.25 <0.0001 0.0002 <0.0001 0.0306 0.0136 0.9995 --- 
2.5 <0.0001 <0.0001 0.0006 0.0069 0.0151 0.4107 --- 
5 <0.0001 0.0003 0.0908 0.0502 0.2734 0.0200 --- 
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Table 13. P-values of t-tests comparing normalized lipoate reduction of varying 
concentrations of compound to that of other concentrations of the same compound. Values 
less than 0.05 are significant. 
Compound [Compound] (µM) 0.15625 0.3125 0.625 1.25 2.5 5 
Dox 
0.15625 --- 0.7466 0.7963 0.2990 0.1632 0.2502 
0.3125 0.7466 --- 0.5709 0.1769 0.0997 0.2224 
0.625 0.7963 0.5709 --- 0.3888 0.3403 0.5455 
1.25 0.2990 0.1769 0.3888 --- 0.9503 0.8597 
2.5 0.1632 0.0997 0.3403 0.9503 --- 0.8496 
5 0.2502 0.2224 0.5455 0.8597 0.8496 --- 
8 
0.15625 --- 0.4796 0.3585 0.9161 0.0007 0.0006 
0.3125 0.4796 --- 0.9209 0.4320 0.0076 0.0034 
0.625 0.3585 0.9209 --- 0.3525 0.0006 0.0001 
1.25 0.9161 0.4320 0.3525 --- 0.0001 <0.0001 
2.5 0.0007 0.0076 0.0006 0.0001 --- 0.0084 
5 0.0006 0.0034 0.0001 <0.0001 0.0084 --- 
4 
0.15625 --- 0.8755 0.9860 0.2661 0.0155 0.0021 
0.3125 0.8755 --- 0.8235 0.1618 0.0073 0.0021 
0.625 0.9860 0.8235 --- 0.1084 0.0018 0.0003 
1.25 0.2661 0.1618 0.1084 --- 0.1388 0.0157 
2.5 0.0155 0.0073 0.0018 0.1388 --- 0.0247 
5 0.0021 0.0021 0.0003 0.0157 0.0247 --- 
9 
0.15625 --- 0.4423 0.3830 0.5043 0.1063 0.0015 
0.3125 0.4423 --- 0.0977 0.1153 0.0245 0.0014 
0.625 0.3830 0.0977 --- 0.5365 0.2941 0.0008 
1.25 0.5043 0.1153 0.5365 --- 0.0804 <0.0001 
2.5 0.1063 0.0245 0.2941 0.0804 --- 0.0016 
5 0.0015 0.0014 0.0008 <0.0001 0.0016 --- 
Aura 
0.15625 --- 0.3088 0.0284 0.0139 <0.0001 0.0006 
0.3125 0.3088 --- 0.0363 0.0121 <0.0001 <0.0001 
0.625 0.0284 0.0363 --- 0.3987 0.0004 <0.0001 
1.25 0.0139 0.0121 0.3987 --- 0.0039 0.0002 
2.5 <0.0001 <0.0001 0.0004 0.0039 --- <0.0001 
5 0.0006 <0.0001 <0.0001 0.0002 <0.0001 --- 
1:2 4:8 
0.15625 --- 0.0959 0.0043 0.0003 0.0003 0.0002 
0.3125 0.0959 --- 0.7326 0.9198 0.2593 0.2582 
0.625 0.0043 0.7326 --- 0.6027 0.1894 0.1335 
1.25 0.0003 0.9198 0.6027 --- 0.0295 0.0070 
2.5 0.0003 0.2593 0.1894 0.0295 --- 0.7122 
5 0.0002 0.2582 0.1335 0.0070 0.7122 --- 
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Figure 46. Normalized lipoate reduction with standard error in A549 over 3 hours, after 6 
hours incubation in 2.5 µM compound. 
Figure 47. Normalized lipoate reduction with standard error in A549 over 3 hours, after 
incubation in 1.25 µM compound. 
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